Rhythm Pharmaceuticals Inc. (RYTM) exhibits 89.7% gross margins and -29.6% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 89.7% gross profitability converts into -60.0% operating margin and -29.6% ROIC, outpacing sector cost of capital.
ROIC: -29.6% // GM: 89.7%YoY revenue trajectory of +45.8% paired with -1.82% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +45.8% // FCF YLD: -1.82%Altman Z-Score of 14.33 and Piotroski F-Score of 5/9 indicate low near-term refinancing stress.
ALTMAN Z: 14.33 // F-SCORE: 5/9Trading at 24.0x trailing P/E (33.0x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $93.44 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend -0.1% net margins.
NET MARGIN: -0.1% // D/E: 0.73x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for RYTM & activate live FRED threshold breach alerts.